AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 20, 2024 09:25 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
logo 600X600.png
Feeding Tubes Market Size to Surpass Around US$ 9.69 Billion 2030, Recording a CAGR of 6.2% | Report by CoherentMI
March 20, 2024 06:21 ET | CMI
Burlingame, March 20, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Feeding Tubes Market was valued at US$ 6.34 Billion in the year 2023 and is anticipated to reach US$ 9.69...
OBI Logo.jpg
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
March 18, 2024 05:00 ET | OBI Pharma Inc.
TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC)....
OBI Logo.jpg
浩鼎将在 AACR 2024 年会   发表四篇论文
March 18, 2024 05:00 ET | OBI Pharma Inc.
台湾台北电, March 18, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174)旗下自行开发的抗TROP2抗体药物复合体(ADC)OBI-992,临床前数据证明,它在多种动物实验模式均显示高效的抗 肿瘤活性、优异的药物动力学表现,和良好的安全性,具有发展为同类最佳抗TROP2 ADC的潜力。...
OBI Logo.jpg
浩鼎將在 AACR 2024 年會 發表四篇論文
March 18, 2024 05:00 ET | OBI Pharma Inc.
台灣台北電, March 18, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174)旗下自行開發的抗TROP2抗體藥物複合體(ADC)OBI-992,臨床前數據證明,它在多種動物實驗模式均顯示高效的抗腫瘤活性、優異的藥物動力學表現,和良好的安全性,具有發展為同類最佳抗TROP2...
CURE Media Group and Oncology Nursing News Announces the 2024 Extraordinary Healer® Award Finalists
March 15, 2024 12:00 ET | CURE Media Group
CRANBURY, N.J., March 15, 2024 (GLOBE NEWSWIRE) -- CURE® Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients,...
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
March 15, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM...
Immuneering-logo (1).png
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
March 14, 2024 07:00 ET | Immuneering Corporation
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for...
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
March 14, 2024 02:00 ET | Anocca AB
NEW YORK and SÖDERTÄLJE, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc....
Novotech Publishes Precision Oncology Landscape Whitepaper Identifying Current Trends and Opportunities in Targeted Therapies
March 12, 2024 20:01 ET | Novotech
Novotech CRO has released an insightful whitepaper, Precision Oncology - Global Clinical Trial Landscape, providing the latest research insights for cancer